Clinical Trials and Research Program

Principal Investigator:
Mahmood Razavi, MD

Co-Investigators:
Kurt Openshaw, MD
Howard Dorne, MD
D. Preston Flanigan, MD
Michael Chan, MD

Open to enrollment

ATTRACT: Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis

This is a NIH-funded, Phase III, multi-center, randomized, open-label, assessor-blind, parallel two-arm, controlled clinical trail. The primary objective is to determine if the initial use of Pharmacomechanical Catheter-Directed Thrombolysis (PCDT) in symptomatic patients with acute proximal deep vein thrombosis (DVT) reduces the occurrence of the Post-Thrombotic Syndrome over 24 months follow-up.

Sponsor: NIH and Washington University

Principal Investigator:
Mahmood Razavi, MD

Co-Investigators:
Lawrence Santora, MD
Jairo Marin, MD
Lisa Evans, NP
Lupe Ramos, NP

Open to Enrollment

SYMPLICITY HTN-3: Renal Denervation in Patients with Uncontrolled Hypertension

This is an international, multi-center, prospective, single-blind, randomized and controlled study. Its objective is to demonstrate that catheter-based renal denervation is a safe and effective treatment for uncontrolled hypertension.

Sponsor: Medtronic

Principal Investigator:
Mahmood Razavi, MD

Co-Investigators:
Kurt Openshaw, MD
Howard Dorne, MD
D. Preston Flanigan, MD
Timothy Harward, MD
Jeffrey Ballard, MD

Active. Closed to Enrollment

DURABILITY II: The US Study for Evaluating Endovascular Treatments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By Using the Protégé Everflex Nitinol Stent System II

A prospective, multi-center, non-randomized study. The objective of the study is to evaluate the safety and effectiveness of primary stenting using the Protégé Everflex Self-Expanding Stent System compared to PTA performance goals for the treatment of stenotic, restenotic (from PTA only) or occluded lesions (non-stented) of the native superficial femoral artery or the superficial femoral and proximal popliteal arteries.

Sponsor: Covidien/ev3

Principal Investigator:
Mahmood Razavi, MD

Co-Investigators:
Kurt Openshaw, MD
Howard Dorne, MD

Active. Closed to Enrollment

RENOVA: A Prospective, Randomized, Concurrently-Controlled Post-Approval Study of the FLAIR Endovascular Stent Graft

A prospective, multi-center, randomized concurrently-controlled study of two approaches to the treatment of subjects with stenotic lesions at the venous anastomosis of synthetic arteriovenous (AV) grafts placed to facilitate vascular access for hemodialysis. The purpose of the study is to compare effectiveness data on subjects randomized to treatment with percutaneous transluminal angioplasty and the FLAIR Endovascular Stent Graft versus subjects randomized to treatment with PTA only.

Sponsor: BARD Peripheral Vascular

Co-Investigator:
Michael Chan, MD
Donald Mahon, MD
Lawrence Santora, MD
Tyson Cobb, MD
George Wesley, MD

Active. Closed to Enrollment

CYPRESS: A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different durations of Dual Antiplatelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHER® Stent

During Phase I (non-randomized phase) of this study, the primary objective is to assess the rate of target lesion failure in all-corner and on-label subjects implanted with the CYPHER® stent in native coronary artery or coronary artery bypass graft lesions. During Phase II (randomized phase) of this study, the primary objective is to assess safety (major and minor bleeding), MACCE, and ST rates in all-corner subjects treated with dual antiplatelet therapy for 12 or 30 months following CYPHER® stent implantation.

Sponsor: J&J Cordis